Myelodysplastic Syndromes
The latest news, research, and perspectives in myelodysplastic syndromes (MDS). Subtypes of this heterogeneous group of disorders occur when blood-forming cells in the bone marrow become abnormal. Sometimes, MDS precedes acute myeloid leukemia.
Advertisement
More than 240 meetings were held with members of Congress as part of the ASCO 10th Annual Advocacy Summit.
This agent which has newly received an ODD for MDS recalibrates the immune system to attack hematological and solid tumors.
Overall survival was also greater in the study comparing the treatments in ALL, AML, MDS, and mixed-phenotype acute leukemia.
Melody Smith, MD, MS, shares data on burnout in hematologist oncologists, why it occurs, and how to prevent it.
The approval was based on the phase 3 IMerge study, which showed improved rates of transfusion independence with imetelstat.
MRD testing before HSCT may offer insight into survival outcomes for patients with MDS/MPN.
Advertisement
The phase 2 prospective trial with these results also evaluated overall survival, nonrelapse mortality, and relapse rates.
Lenalidomide is indicated to treat myeloma in combination with dexamethasone and transfusion-dependent anemia due to MDS.
Nicole Grieselhuber, MD, PhD on results of SEA-CD70 treatment in patients with high-risk MDS.
Drs. Thomas LeBlanc, Jamie Koprivnikar, and Andrew Brunner give their predictions for the future of MDS management.
An expert panel delves into new data regarding the long-term efficacy of luspatercept in MDS.
An expert MDS panel discusses patient reported outcomes, transfusion dependence, and time toxicity.
This new indication for the injection alkylating agent pertains to adult or pediatric patients aged one year and older.
The COMMANDS trial evaluated frontline luspatercept in transfusion-dependent patients with lower-risk MDS and anemia.
Issues addressed include mandatory versus optional biopsy, informed consent, and safety in both adult and pediatric patients.
HMAs, either as monotherapy or in combination with venetoclax, represent the standard of care for higher-risk MDS or AML.
According to a study, patients with MDS and CMML have dismal clinical outcomes after failure of HMA therapy.
Investigational combinations for MDS appeared to be well tolerated while triplets results in high-grade toxicity.
An expert speaks on site at ASH 2024 about the health-related quality of life data from the phase 3 COMMANDS trial.
Phase 2 study results outline benefit of adding venetoclax to intensive chemo in MDS and AML patients.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.